Bullish Case: Q2 beat ($410.26M, +13%) with raised FY guide despite a sell-the-news flush from an overheated +46% August run. Short interest at 21.8% is fuel for a squeeze; analysts re-rated targets (Needham $22, UBS $19). Helium-vs-market density shows a fat secondary bump at ~$20.5 and the term structure flattens after Sep 26 (IV 55–68%), suggesting the post-earnings shock decays and mean-reversion toward $14.5–15.5 takes hold.

Bearish Case: The drop came despite a beat and raise — the market repriced slower Q3 growth and gross margin compression (80% vs 82%). PATH fell 25.5% in a week; backwardated front IV (Helium 121%/market 132% on Sep 12) shows crash protection still bid. Retail 'extremely bullish' euphoria + crowded tech fund outflows (-$1.4B) set up continued de-rating; the Helium density puts meaningful mass at $12.5–13.5 and a left tail toward $9–10.

Potential Outcomes:

1. 35%: Base $13.0–14.5 by Oct 10 — post-earnings IV crush (Helium 55–60% vs 121% front) favors drift; falsifiable: realized move stays within ±7%.
2. 25%: Squeeze +10–20% to $15–16.5 — 21.8% short interest covers; falsifiable: 10/16 $15/$16 calls (61–62% IV) rally and put skew compresses.
3. 25%: Drift lower $11.5–12.5 — margin/Q3-growth doubts plus tech outflows; falsifiable: 12/18 $13 puts (70.8% IV, 5.5k volume) print above $2.50.
4. 15%: Tail <$10 — SPY risk-off (elevated surface) transmits; falsifiable: Jan $10 puts (74% IV, -0.17 delta) triple.

September 10, 2026